We are 3,4-Dihydroxybenzaldehyde CAS:139-85-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests
CAS No: 139-85-5
Product Name: 3,4-Dihydroxybenzaldehyde
Other Name:
3,4-Dihydroxybenzaldehyde
Protocatechualdehyde
1,2-dihydroxy-4-formylbenzene
4-formyl-1,2-benzenediol
3,4-Dihydroxybenzyl aldehyde
4-formyl-1,2-dihydroxybenzene
Protocatechuic aldehyde
Density: 1.4±0.1 g/cm3
Boiling Point: 295.4±20.0 °C at 760 mmHg
Melting Point: 150-157 °C(lit.)
Molecular Formula: C7H6O3
Molecular Weight: 138.12
Flash Point: 146.7±18.3 °C
Exact Mass: 138.031693
PSA: 57.53000
LogP: 1.14
Vapour Pressure: 0.0±0.6 mmHg at 25°C
Index of Refraction: 1.674
Storage condition: 2-8°C
Stability: Stable. Incompatible with strong bases, strong oxidizing agents.
Water Solubility: 50 g/L (20 ºC)
Specification
Appearance: Light gray or off-white crystalline powder
Assay: ≥99.0%
Water: ≤0.50%
Application
Protocatechuic aldehyde has anti-inflammatory and coronary blood flow increasing effects. It is an active ingredient in angina pallidum and is one of the main active ingredients in the treatment of nephritis. Also used in perfume synthesis.
Protocatechuic aldehyde can be used as a precursor in the vanillin synthesis by biotransformation by cell cultures of Capsicum frutescens, a type of Chili pepper. It is also found in the mushroom Phellinus linteus.
Protocatechualdehyde (Catechaldehyde), a natural polyphenol compound isolated from the roots of radix Salviae Miltiorrhizae, is associated with a wide variety of biological activities and has been widely used in medicine as an antioxidant, anti-aging, an antibacterial and anti-inflammatory agent.
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Related News: API and raw material are often confused due to the similar usage of the two terms.2-fluoro-4-metoxibenzonitrilo CAS:94610-82-9 The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.6-Chloroimidazo[1,2-b]pyridazine According to the “2013-2018 New Drug Review Summary” report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years.408-27-5 The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations.The complete chemical and pharmaceutical industry chain consists of basic chemical raw materials, pharmaceutical intermediates, chemical raw materials and chemical preparations.
